• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

氟-18 标记的 Fluciclovine PET/CT 在原发性和生化复发前列腺癌管理中的应用。

Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management.

机构信息

Department of Radiology, West Virginia University Health Sciences Center, 1 Medical Center Dr, Morgantown, WV 26505.

Department of Radiology, UT Southwestern Medical Center, Dallas, TX.

出版信息

AJR Am J Roentgenol. 2020 Aug;215(2):267-276. doi: 10.2214/AJR.19.22404. Epub 2020 Jun 17.

DOI:10.2214/AJR.19.22404
PMID:32551903
Abstract

The purpose of this article is to review the utility of F-fluciclovine PET/CT in the evaluation of recurrent prostate cancer. Fluorine-18-labeled fluciclovine PET/CT has shown promise in the evaluation of recurrent prostate cancer. Its performance has been superior to that of other imaging modalities. It has had good diagnostic accuracy, especially in the detection of extra-prostatic disease recurrence, and the findings have an impact on treatment planning. Gallium-68-labeled prostate-specific membrane antigen PET/CT has also had excellent performance in the detection of biochemically recurrent prostate cancer with detection rates superior to those of fluciclovine PET/CT.

摘要

本文旨在回顾 F-氟代盐酸仑伐替尼 PET/CT 在复发性前列腺癌评估中的应用。氟[18F]氟代盐酸仑伐替尼 PET/CT 在复发性前列腺癌的评估中显示出了一定的前景。其性能优于其他成像方式。它具有良好的诊断准确性,特别是在检测前列腺外疾病复发方面,其结果对治疗计划有影响。镓[68Ga]标记的前列腺特异性膜抗原 PET/CT 在检测生化复发的前列腺癌方面也具有优异的性能,其检测率优于氟代盐酸仑伐替尼 PET/CT。

相似文献

1
Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management.氟-18 标记的 Fluciclovine PET/CT 在原发性和生化复发前列腺癌管理中的应用。
AJR Am J Roentgenol. 2020 Aug;215(2):267-276. doi: 10.2214/AJR.19.22404. Epub 2020 Jun 17.
2
PSMA-targeted Radiotracers versus F Fluciclovine for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis.PSMA 靶向放射性示踪剂与 F 氟脱氧葡萄糖(18F-Fluciclovine)在明确治疗后前列腺癌生化复发检测中的比较:系统评价和荟萃分析。
Radiology. 2020 Jul;296(1):44-55. doi: 10.1148/radiol.2020191689. Epub 2020 May 12.
3
F-fluciclovine PET-CT and Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.氟[¹⁸F]氟代脱氧葡萄糖 PET-CT 和镓[⁶⁸Ga]前列腺特异性膜抗原-11 PET-CT 在前列腺癌根治术后早期生化复发患者中的应用:一项前瞻性、单中心、单臂、对比成像试验。
Lancet Oncol. 2019 Sep;20(9):1286-1294. doi: 10.1016/S1470-2045(19)30415-2. Epub 2019 Jul 30.
4
Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.使用抗3-[(18)F]FACBC PET/CT检测复发性前列腺癌:与CT的比较。
Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1773-83. doi: 10.1007/s00259-016-3383-8. Epub 2016 Apr 18.
5
Utility of F-Fluciclovine PET/CT for Detecting Prostate Cancer Recurrence in Patients With Low (< 1 ng/mL) or Very Low (< 0.3 ng/mL) Prostate-Specific Antigen Levels.F-氟代脱氧葡萄糖 PET/CT 在检测前列腺特异性抗原水平较低(<1ng/mL)或极低(<0.3ng/mL)的前列腺癌患者复发中的应用。
AJR Am J Roentgenol. 2020 Oct;215(4):997-1001. doi: 10.2214/AJR.19.22180. Epub 2020 Jun 22.
6
Fluorine-18-Labeled Fluciclovine PET/CT in Clinical Practice: Factors Affecting the Rate of Detection of Recurrent Prostate Cancer.氟-18 标记的 Fluciclovine PET/CT 在临床实践中的应用:影响复发性前列腺癌检出率的因素。
AJR Am J Roentgenol. 2019 Oct;213(4):851-858. doi: 10.2214/AJR.19.21153. Epub 2019 Jun 19.
7
The Clinical Utility of F-Fluciclovine PET/CT in Biochemically Recurrent Prostate Cancer: an Academic Center Experience Post FDA Approval.氟[¹⁸F]脱氧葡萄糖(F-Fluciclovine) PET/CT 在生化复发前列腺癌中的临床应用:美国食品和药物管理局(FDA)批准后的学术中心经验。
Mol Imaging Biol. 2021 Aug;23(4):614-623. doi: 10.1007/s11307-021-01583-3. Epub 2021 Jan 19.
8
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
9
Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment.氟脱氧葡萄糖 PET/CT 与盆腔多参数 MRI 对初始治疗后 PSA 升高的前列腺癌盆腔诊断效能的比较。
Clin Nucl Med. 2020 May;45(5):349-355. doi: 10.1097/RLU.0000000000002963.
10
A review discussing fluciclovine (F) PET/CT imaging in the detection of recurrent prostate cancer.探讨氟尿嘧啶(F) PET/CT 成像在检测复发性前列腺癌中的应用的综述。
Future Oncol. 2018 May;14(11):1101-1115. doi: 10.2217/fon-2017-0446. Epub 2018 Jan 23.

引用本文的文献

1
[F]PSMA-1007 PET/MR as a Precision Biomarker for Early Detection of Biochemical Recurrence in Prostate Cancer at Very Low PSA Levels.[F]PSMA - 1007正电子发射断层扫描/磁共振成像作为极低前列腺特异抗原水平下前列腺癌生化复发早期检测的精准生物标志物
Biomark Insights. 2025 Mar 12;20:11772719251324307. doi: 10.1177/11772719251324307. eCollection 2025.
2
The Impact of PSMA PET/CT on Modern Prostate Cancer Management and Decision Making-The Urological Perspective.前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描对现代前列腺癌管理和决策的影响——泌尿外科视角
Cancers (Basel). 2023 Jun 29;15(13):3402. doi: 10.3390/cancers15133402.
3
Detection Rate and Clinical Impact of PET/CT with F-FACBC in Patients with Biochemical Recurrence of Prostate Cancer: A Retrospective Bicentric Study.
¹⁸F-FACBC PET/CT在前列腺癌生化复发患者中的检测率及临床影响:一项回顾性双中心研究
Biomedicines. 2022 Jan 15;10(1):177. doi: 10.3390/biomedicines10010177.
4
Clinical utility of F-Fluciclovine PET/CT in recurrent prostate cancer with very low (≤0.3 ng/mL) prostate-specific antigen levels.F-氟代脱氧胸苷PET/CT在前列腺特异性抗原水平极低(≤0.3 ng/mL)的复发性前列腺癌中的临床应用价值
Am J Nucl Med Mol Imaging. 2021 Oct 15;11(5):406-414. eCollection 2021.